GC3111A / GC Biopharma - LARVOL DELTA

A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults (clinicaltrials.gov) - P1/2 | N=120 | Recruiting | Sponsor: GC Biopharma Corp | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus

A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults (clinicaltrials.gov) - P1/2 | N=120 | Not yet recruiting | Sponsor: GC Biopharma Corp

New P1/2 trial • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus

Immunogenicity of a new enhanced tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine against Bordetella pertussis in a murine model. (PubMed, BMC Immunol) - "Our results confirmed the immunogenicity of GC Pharma's Tdap vaccine; enhanced GC3111 was equivalent to the presently used commercial vaccine in terms of humoral response as well as cell-mediated cytokine expression."

Journal • Preclinical • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus • IFNG • IL17A • IL5

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults (clinicaltrials.gov) - P2; N=213; Recruiting; Sponsor: Green Cross Corporation

Clinical • New P2 trial